Hospital‐acquired infections ( · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
1 finding from 1 review
Invasive fungal infection · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
1 finding from 1 review
All‐cause mortality up to 30 days · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
It is very uncertain whether summary of findings table ‐ Methylprednisolone changes all‐cause mortality up to 30 days compared with dexamethasone (very low certainty).
1 finding from 1 review
Change in visual acuity (logMAR) ‐ 12 months (negative is better) · macular edema in diabetes
1 finding from 1 review
Cataract progression · macular edema in diabetes
Intravitreal dexamethasone implant 0.7 mg probably leads to higher cataract progression ‐ 12 to 24 months compared with intravitreal antiVEGF (moderate certainty).
1 finding from 1 review
RR 4.23 [2.36, 7.59]
Studies not reported
Moderate
Use of IOP‐lowering medications ‐ 24 months · macular edema in diabetes
Intravitreal dexamethasone implant 0.7 mg probably leads to higher use of IOP‐lowering medications ‐ 24 months compared with intravitreal antiVEGF (moderate certainty).
1 finding from 1 review
RR 4.76 [2.84, 7.99]
Studies not reported
Moderate
Surgery for glaucoma ‐ 24 months · macular edema in diabetes
It is very uncertain whether intravitreal dexamethasone implant 0.7 mg changes surgery for glaucoma ‐ 24 months compared with intravitreal antiVEGF (very low certainty).
1 finding from 1 review
RR 3.02 [0.12, 73.56]
Studies not reported
Very low
Change in visual acuity (logMAR) ‐ 12 months (negative is better) · macular edema in diabetes
1 finding from 1 review
Gain 3+ lines of visual acuity at 1 year · macular edema in diabetes
Intravitreal fluocinolone acetonide implant 0.19 mg probably leads to higher gain of three or more lines visual acuity ‐ 12 months compared with sham (moderate certainty).
1 finding from 1 review
Change in retinal thickness (micron) ‐ 12 months (negative is better) · macular edema in diabetes
1 finding from 1 review
Cataract progression ‐ 24 months · macular edema in diabetes
Intravitreal fluocinolone acetonide implant 0.19 mg probably leads to higher cataract progression ‐ 24 months compared with sham (moderate certainty).
1 finding from 1 review
Use of IOP‐lowering medications ‐ 24 months · macular edema in diabetes
Intravitreal fluocinolone acetonide implant 0.19 mg probably leads to higher use of IOP‐lowering medications ‐ 24 months compared with sham (moderate certainty).
1 finding from 1 review
Surgery for glaucoma ‐ 24 months · macular edema in diabetes
Intravitreal fluocinolone acetonide implant 0.19 mg may leads to higher surgery for glaucoma ‐ 24 months compared with sham (low certainty).
1 finding from 1 review
Visual acuity · macular edema in diabetes
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Gain 3+ lines of visual acuity at 1 year · macular edema in diabetes
Intravitreal dexamethasone implant 0.7 mg showed no clear difference in gain of three or more lines visual acuity ‐ 12 months compared with sham (moderate certainty).
1 finding from 1 review
Gain of 3 or more lines of visual acuity · macular edema in diabetes
It is very uncertain whether intravitreal triamcinolone acetonide injection 4 mg changes gain of three or more lines visual acuity ‐ 24 months** compared with sham (very low certainty).
1 finding from 1 review
RR 4.12 [0.48, 34.99]
Studies not reported
Very low
Change in retinal thickness (micron) (negative is better) · macular edema in diabetes
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Cataract progression ‐ 24 months · macular edema in diabetes
Intravitreal triamcinolone acetonide injection 4 mg showed no clear difference in cataract progression ‐ 24 months compared with sham (low certainty).
1 finding from 1 review
RR 3 [0.97, 9.3]
Studies not reported
Low
Use of IOP‐lowering medications ‐ 24 months · macular edema in diabetes
It is very uncertain whether intravitreal triamcinolone acetonide injection 4 mg changes use of IOP‐lowering medications ‐ 24 months compared with sham (very low certainty).
1 finding from 1 review
RR 21.6 [1.32, 354.7]
Studies not reported
Very low
Surgery for glaucoma ‐ 24 months · macular edema in diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found